Profound Medical (PROF) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
TriSalus Life Sciences (TLSI) has outperformed Profound Medical (PROF) over the past year, losing 11.1% versus a loss of 12.1%. Over five years, TLSI leads with a -57.1% price change compared with -62.2% for PROF. TriSalus Life Sciences is the larger company by market cap ($254.3 million vs $252.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PROF | TLSI |
|---|---|---|
| Share price | $6.91 | $4.13 |
| Market cap | $252.49M | $254.30M |
| 1-day change | +21.65% | -2.82% |
| YTD return | -27.83% | -39.11% |
| 1-year return | -12.07% | -11.09% |
| 5-year return | -62.16% | -57.07% |
| EPS (TTM) | $-0.99 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.95 | $7.95 |
| 52-week low | $4.80 | $2.20 |
| Distance from 52-week high | -22.79% | -48.05% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +61.22% | +151.82% |
| Average volume | 124.80K | 276.43K |
| Shares outstanding | 36.54M | 61.57M |
| Employees | 162 | 102 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Profound Medical
PROF stock →Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue.
Health Care · Medical/Dental Instruments · 162 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
PROF vs TLSI FAQ
Which is bigger, Profound Medical or TriSalus Life Sciences?
TriSalus Life Sciences (TLSI) is larger, with a market capitalization of $254.30M compared with $252.49M for Profound Medical (PROF).
Which stock has performed better over the past year, PROF or TLSI?
TLSI returned -11.09% over the past 12 months, compared with -12.07% for PROF (price return, excluding dividends). Past performance does not predict future results.
Are Profound Medical and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Profound Medical and Medical Specialities for TriSalus Life Sciences.